Catalyst Oncology

Conclusions: SD8 inhibits hTopoII in vitro without inducing DNA strands breaks and has significant activity against NSCLC and MM cell lines. While doses required for SD8 anticancer activity are unlikely to be achieved in vivo, chemical modifications to SD8 to increase its potency could lead to improved therapies for these diseases. Content Type Journal ArticleCategory Preclinical StudiesDOI 10.1007/s10637-008-9209-1Authors Ahad A. Sadiq, University of Minnesota Medical School Division of He

View original post here:
Anti-proliferative effects of simocyclinone d8 (sd8), a novel catalytic inhibitor of topoisomerase ii